Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer

The combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is the standard of care for advanced pancreatic cancer, but causes hematological and gastrointestinal toxicities, leading to treatment delay and dose reduction; optimal modification based on toxicities is needed. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Satoshi, Ueno, Makoto, Omae, Katsuhiro, Kuramochi, Hidekazu, Terao, Masato, Mizuno, Nobumasa, Ozaka, Masato, Ueno, Hideki, Uesugi, Kazuhiro, Kobayashi, Noritoshi, Kobayashi, Marina, Todaka, Akiko, Fukutomi, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442997/
https://www.ncbi.nlm.nih.gov/pubmed/30956757
http://dx.doi.org/10.18632/oncotarget.26633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442997/
https://www.ncbi.nlm.nih.gov/pubmed/30956757
http://dx.doi.org/10.18632/oncotarget.26633

Ejemplares similares